Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03556839 · ClinicalTrials.gov registry record · Phase 3
Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix
A Phase 3 study of Carcinoma of the Cervix, Stage IVB, sponsored by Grupo Español de Investigación en Cáncer de Ovario.
- Active
- Registry status
- Phase 3
- Development phase
- 410
- Enrollment target
- 20
- Study locations
NCT03556839: Active Phase 3 study of Carcinoma of the Cervix, Stage IVB, sponsored by Grupo Español de Investigación en Cáncer de Ovario.
NCT03556839 is a Phase 3 study of Carcinoma of the Cervix, Stage IVB that is active but no longer recruiting, run by Grupo Español de Investigación en Cáncer de Ovario. The registered enrollment target is 410 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03556839, a Phase 3 study of Carcinoma of the Cervix, Stage IVB, is active but no longer recruiting, sponsored by Grupo Español de Investigación en Cáncer de Ovario.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 410 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will integrate the efficacy of combining the anti programmed death-ligand 1 (anti-PD-L1) agent atezolizumab with the current standard of care in Stage IVB , persistent or recurrent carcinoma of the cervix, namely cisplatin or carboplatin/paclitaxel/bevacizumab. It will be explored the combination of bevacizumab plus atezolizumab, with no patient selection based on PD-L1 expression, allowing an all-comer assessment of atezolizumab activity. The study is a randomized open label phase III trial to investigate the impact of atezolizumab in combination with bevacizumab and cisplatin or carboplatin /paclitaxel chemotherapy on overall survival and will employ the intent to treat principle, and random assignment to one of the 2 arms will be balanced according to disease histology (squamous cell carcinoma vs adenocarcinoma), prior platinum therapy as a radiation sensitizer (no prior cis-Radiotherapy (RT) versus prior cis-RT) and chemotherapy backbone (cisplatin vs carboplatin). This trial will be run in an open label design due to the following considerations: the control arm is the standard of care for women diagnosed with metastatic, persistant or recurrent cervical cancer because of its impact on overall survival and the primary endpoint of the study is overall survival (OS), so blinding is not needed to ensure a robust assessment.
Primary Outcome
Time from the date of randomization to the date of first documentation of disease progression or death due to any cause, whichever occurs first based on investigator assessment using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Paclitaxel
- DRUG Cisplatin/Carboplatin
Study Locations (20)
Other
- ICO Paul Papin - Angers
- CHU Jean Minjoz - Besançon
- Institut Bergonié - Bordeaux
- Centre François Baclesse - Caen
- Centre Oscar Lambret - Lille
- Centre Léon Bérard - Lyon
- ICM Val d'Aurelle - Montpellier
- Hôpital Privé du Confluent S.A.S. - Nantes
- Centre Antoine Lacassagne - Nice
- Groupe Hospitalier Diaconesses-Croix Saint-Simon - Paris
- HEGP - Paris
- Centre Hospitalier Lyon Sud - Pierre-Bénite
- Centre CARIO-HPCA - Plérin
- ICO Centre René Gauducheau - Saint-Herblain
- Hôpitaux Universitaires - Strasbourg
- Institut Claudius Régaud - Toulouse
- Gustave Roussy - Villejuif
- Universitätsmedizin Mainz - Mainz
Louisiana
- Willis Knighton Cancer Center - Shreveport
Virginia
- Massey Cancer Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 410 participants |
| Start Date | 2018-09-25 |
| Est. Completion | 2025-08 |
| Phase | Phase 3 |
What the registry record for NCT03556839 still lists
NCT03556839 is an interventional study that assigns participants to a tested intervention. The registered 410 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Carcinoma of the Cervix, Stage IVB appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT03556839 names 20 study sites across 3 states, led by Other, Louisiana, Virginia.
Frequently Asked Questions
What is clinical trial NCT03556839 about?
NCT03556839 is a clinical study titled "Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix". The study will integrate the efficacy of combining the anti programmed death-ligand 1 (anti-PD-L1) agent atezolizumab with the current standard of care in Stage IVB , persistent or recurrent carcinoma of the cervix, namely cisplatin or carboplatin/paclitaxel/bevacizumab. It will be explored the comb...
What is the current status of trial NCT03556839?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 410 participants. The study started on 2018-09-25. Estimated completion is 2025-08.
What conditions does trial NCT03556839 study?
This clinical trial studies the following conditions: Carcinoma of the Cervix, Stage IVB.
What interventions are being tested in trial NCT03556839?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Paclitaxel (DRUG), Cisplatin/Carboplatin (DRUG).
Who is sponsoring clinical trial NCT03556839?
This trial is sponsored by Grupo Español de Investigación en Cáncer de Ovario, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03556839 being conducted?
This trial has 20 study locations across Louisiana, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03556839's enrollment target sits among peer trials
410 909th of 2000 higher than 1,090 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
- NCT05730036 · 410 participants · Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- NCT05751473 · 410 participants · NA
Reducing Posttraumatic Stress Disorder (PTSD) Symptoms in First Responders and Frontline Health Care Workers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI